Johns Hopkins is home to the Specialized Program of Research Excellence (SPORE) in Cervical Cancer, a multimillion-dollar grant from the National Cancer Institute (NCI) to explore groundbreaking cervical cancer research, prevention, and treatment. Johns Hopkins has been the home to this project since 2003. The goal of the Cervical Cancer SPORE is to reduce the incidence, morbidity, and mortality related to cervical cancer by developing next-generation therapeutic human papillomavirus (HPV) vaccines for clinical translation. SPORE projects are translational in Nature and address diagnosis, detection, prevention, treatment, and risk assessment for cervical cancer.

The Cervical Cancer SPORE is led by Program Director Dr. T.-C. Wu, M.D., Ph.D. and is a collaboration between Johns Hopkins University, University of Alabama at Birmingham, University of Colorado Boulder, and Medical University of Vienna.